Roche reports 1H13 sales of new cancer drugs

Roche (SIX:ROG; OTCQX:RHHBY) reported 1H13 earnings on Thursday, including sales for its two newest drugs for HER2-positive metastatic breast cancer. The pharma recorded sales of CHF108 million ($114.9 million) in worldwide 1H13 sales of Perjeta pertuzumab, which Roche launched in the EU in March and in the U.S. last June. Sales of Kadcyla ado-trastuzumab emtansine ( T-DM1), which the pharma launched in the U.S. in February and in Switzerland in May, were CHF83 million ($88.3 million).

Roche also said Kadcyla met the primary endpoint of progression-free survival (PFS) vs. physician's choice of therapy in the Phase III TH3RESA trial for third-line treatment for HER2-positive metastatic breast cancer. The pharma said overall survival (OS) data were not yet mature. Kadcyla is approved for second-line HER-positive breast cancer. ...